Delumeau J C, Bentué-Ferrer D, Gandon J M, Amrein R, Belliard S, Allain H
Laboratory of Experimental and Clinical Pharmacology, University Hospital, Rennes, France.
J Neural Transm Suppl. 1994;41:259-66. doi: 10.1007/978-3-7091-9324-2_34.
Recent data obtained in animals and in humans suggest that both MAO-A and MAO-B inhibitors present cognitive enhancing properties of possible interest in the treatment of cognitive disorders. In addition, the rational for using selegiline as a neuroprotector in Parkinson's disease may also be applicable in Alzheimer's disease in which a dramatic increase in the MAO-B activity has been reported. It seems then worthwhile to investigate the neuroprotective effect of MAOIs in humans and to assess, furthermore, the real therapeutical benefit of their cognitive enhancing properties.
近期在动物和人类身上获得的数据表明，单胺氧化酶A（MAO-A）抑制剂和单胺氧化酶B（MAO-B）抑制剂都具有认知增强特性，这可能对治疗认知障碍具有重要意义。此外，将司来吉兰用作帕金森病神经保护剂的原理可能也适用于阿尔茨海默病，据报道，阿尔茨海默病患者的MAO-B活性会急剧增加。因此，研究单胺氧化酶抑制剂（MAOIs）在人类身上的神经保护作用，并进一步评估其认知增强特性的实际治疗益处，似乎是值得的。
